BIQOVIZ
Regeneron Pharmaceuticals, Inc.
Mark For: BIQOVIZ™ trademark registration is intended to cover the categories of
| Research |
OneLook
Acronym Finder
|
| Serial Number | 90089032 |
| Mark Literal Elements | BIQOVIZ |
| Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
| Mark Type | TRADEMARK |
| Register | PRINCIPAL |
| Current Location | GENERIC WEB UPDATE 2021-05-10 |
| Basis | 1(b) |
| Class Status | ABANDONED |
| Primary US Classes |
|
| Primary International Class |
|
| Filed Use | No |
| Current Use | No |
| Intent To Use | Yes |
| Filed ITU | Yes |
| 44D Filed | No |
| 44E Current | No |
| 66A Current | No |
| Current Basis | No |
| No Basis | No |
| Attorney Name | Terrence J. McAllister |
| Attorney Docket Number | 554.1745UST1 |
Timeline
| 2020-08-03 | Application Filed |
| 2020-08-06 | Location: NEW APPLICATION PROCESSING |
| 2020-08-06 | Status: Live/Pending |
| 2020-08-06 | Transaction Date |
| 2021-03-30 | Published |
| 2021-05-10 | Location: GENERIC WEB UPDATE |
| 2021-05-10 | Status: Abandoned after publication because applicant filed an express abandonment. To view all documents in this file, click on the Tra |
Trademark Parties (Applicants & Owners)
| Party: |  Regeneron Pharmaceuticals, Inc. |
| Address | 777 Old Saw Mill River Road Tarrytown, NEW YORK UNITED STATES 10591 |
| Legal Entity Type | Corporation |
| Legal Entity State | NEW YORK |
Documents
 Application | MULTI | 2020-08-03 |
 Drawing | JPEG | 2020-08-03 |
| XSearch Search Summary | XML | 2021-02-17 |
| Public Note | 2021-02-20 | |
| TRAM Snapshot of App at Pub for Oppostn | MULTI | 2021-02-23 |
| Notice of Publication | XML | 2021-03-10 |
| Notification Of Notice of Publication | XML | 2021-03-10 |
| OG Publication Confirmation | XML | 2021-03-30 |
| Express Abandonment | XML | 2021-05-05 |
| Notice of Abandonment | XML | 2021-05-10 |
Attorney of Record
Good, Services, and Codes
(ABANDONED)
IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical preparations for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders |
Trademark Filing History
| Description | Date | Proceeding Number |
|---|---|---|
| ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION | 2021-05-10 | |
| ABANDONMENT - AFTER PUBLICATION | 2021-05-10 | |
| TEAS EXPRESS ABANDONMENT RECEIVED | 2021-05-05 | |
| EXTENSION OF TIME TO OPPOSE RECEIVED | 2021-04-27 | |
| PUBLISHED FOR OPPOSITION | 2021-03-30 | |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2021-03-30 | |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2021-03-10 | |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2021-02-20 | |
| ASSIGNED TO EXAMINER | 2021-02-10 | 94057 |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2020-09-01 | |
| NEW APPLICATION ENTERED IN TRAM | 2020-08-06 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 